Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Prostate Adenocarcinoma 1Neoplasms by Site 1Neoplasms 1Male Urogenital Diseases 1Glioblastoma 1Female Urogenital Diseases 1Carcinoma, Transitional Cell 1Brain Neoplasms 1

Interventions

Radiotherapy 2Radiation 2relugolix 1histrelin 1darolutamide 1bicalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Triptorelin Pamoate 1Salicylic Acid 1Radiation Dose Hypofractionation 1Neoadjuvant Therapy 1Leuprolide 1Goserelin 1Flutamide 1Buserelin 1Adjuvants, Pharmaceutic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Prostate Adenocarcinoma × Radiation Dose Hypofractionation × Clear all
NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology

Phase 3 Completed
296 enrolled 29 charts
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡